Operationalizing bispecific antibody therapy in community oncology: Capturing insights on clinician preparedness for using off-the-shelf immunotherapy in lymphoma and multiple myeloma.
Carmine Deluca(Progressive Expert Consulting (United States)), Marina Wanes(Progressive Expert Consulting (United States)), Jennifer L. Crombie(Dana-Farber Cancer Institute), H J Lee(The University of Texas MD Anderson Cancer Center), Amy Goodrich(Sidney Kimmel Comprehensive Cancer Center), Michael Beyer, Jeffrey Yorio(Texas Oncology)
Cited by 0
Related Papers
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
|Blood|2019|187
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
|Blood|2024|132
The treatment of Burkitt lymphoma in adults
|Blood|2020|105
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders
|Frontiers in Oncology|2019|104